DiaMedica Therapeutics Inc. (DMAC)
Market Cap | 106.30M |
Revenue (ttm) | n/a |
Net Income (ttm) | -19.27M |
Shares Out | 37.96M |
EPS (ttm) | -0.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 141,151 |
Open | 3.080 |
Previous Close | 2.950 |
Day's Range | 2.720 - 3.080 |
52-Week Range | 1.938 - 4.400 |
Beta | 1.73 |
Analysts | Strong Buy |
Price Target | 7.00 (+150.0%) |
Earnings Date | Aug 12, 2024 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 150.00% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/b/press17-2504753.jpg)
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced...
![](https://cdn.snapi.dev/images/v1/a/h/press18-2497228.jpg)
DiaMedica Therapeutics Announces $11.8 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...
![](https://cdn.snapi.dev/images/v1/x/d/press20-2497192.jpg)
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce...
![](https://cdn.snapi.dev/images/v1/y/c/press12-2421675.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/x/5/conf20-2406117.jpg)
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/1/p/press7-2376911.jpg)
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/e/f/press11-2331850.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/6/x/press6-2249594.jpg)
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/n/m/press14-2238201.jpg)
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/a/n/press1-2155631.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/a/z/press18-2149723.jpg)
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/j/c/conf7-2141440.jpg)
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/w/e/press20-2059374.jpg)
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/g/1/press14-2051374.jpg)
DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced ...
![](https://cdn.snapi.dev/images/v1/j/p/press5-2022439.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...
![](https://cdn.snapi.dev/images/v1/r/1/conf10-2011863.jpg)
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/y/i/press8-1975733.jpg)
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced ...
![](https://cdn.snapi.dev/images/v1/9/3/press18-1947621.jpg)
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...
![](https://cdn.snapi.dev/images/v1/r/a/press12-1942296.jpg)
DiaMedica Therapeutics Announces $37.5 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...
![](https://cdn.snapi.dev/images/v1/r/g/press17-1942237.jpg)
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...
![](https://cdn.snapi.dev/images/v1/a/d/press10-1912142.jpg)
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the a...
![](https://cdn.snapi.dev/images/v1/5/h/press8-1891031.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...
![](https://cdn.snapi.dev/images/v1/d/n/conf6-1876939.jpg)
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute...
![](https://cdn.snapi.dev/images/v1/m/0/press18-1832277.jpg)
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today anno...
![](https://cdn.snapi.dev/images/v1/t/k/press9-1816077.jpg)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...